



  Asthma is a common disease of chronic airway inflammation that has multiple triggers 
that cause malfunction of the lungs.  Because asthma affects the airways by inducing 
inflammation and causing narrowing, an influenza virus infection is more likely to cause severe 
symptoms in an asthmatic.  As influenza vaccination is the best protection from influenza 
infection, this study was to explore the vaccine response of asthmatic and matched control (i.e. 
non-asthmatic) human subjects. In addition, the effect of BMI on the asthmatic response to 
vaccination was also explored.  Previous work in our lab had demonstrated that increasing BMI 
was associated with a decreased response to vaccination. Therefore, a higher BMI in an 
asthmatic may result in a poorer response to vaccine.  Serum was collected from subjects pre and 
30 days post influenza vaccination. Antibody titers were measured to the H3N2 and H1N1 virus 
strains represented in that year’s (2015) vaccine. There was a significant increase in antibody 
response post vaccination among both asthmatic and control groups.  There was also significant 
difference in asthmatic and control groups between antibody fold increase pre and post 
vaccination with asthmatics having a greater fold increase than the control group.  Pre-
vaccination, asthmatic subjects tended to start with a lower antibody titer and post-vaccination 
had comparable or greater antibody titer than their control counterparts. This suggests that 
asthmatics may not be able to maintain their antibody response to the same extent as non-
asthmatics.  
 
I.   Specific Aims       
Asthma is present on average in 1 in 12 adults.  In the last decade, the proportion of 
people in the United States with asthma grew by 15%1.  The inflammatory disease was 
the most common comorbidity observed among patients hospitalized with influenza A 
virus during the 2009 pandemic2.  Little is known about how the asthmatic phenotype 
influences protective immune responses against respiratory viral pathogens.   
A mouse-model study conducted by Furuya et al. demonstrated a causal link 
between defective antibody responses and heightened susceptibility of asthmatic mice to 
influenza infection2.  This suggests that asthmatics have a defective immune response 
when exposed to the influenza virus when compared to non-asthmatics.  This leads us to 
ask: Will an impaired immune response be observed in human asthmatic subjects and is 
the influenza vaccine as effective in asthmatic subjects? Furthermore, could obesity also 
further impair the asthmatic response to vaccine? 
 
Aim 1: Determine the vaccine antibody titer of matched subjects pre and post vaccination using 
the influenza hemmaglutinaiton inhibition (HAI) assay against the H3N2 virus.  The hypothesis 
is that both asthmatics and non-asthmatics will have a higher antibody titer post vaccination, but 
that asthmatics will have a lower antibody titer for both pre and post vaccination.  
 
Aim 2: Determine the vaccine antibody response of matched subjects pre and post vaccination 
using the HAI assay against the H1N1 virus.  The hypothesis is that both asthmatics and non-
asthmatics will have a higher antibody titer post vaccination, but again asthmatics will have a 
lower antibody titer for both pre and post vaccination.      
 
Aim 3: Determine if increasing BMI contributes to a poorer vaccine response in asthmatics 
compared with controls.  Previous studies have found that obesity results in a weakened immune 
response.  The hypothesis is that asthmatics in the obese class I and II BMI category (i.e. 4 and 
5) will have a lower antibody titer than obese non-asthmatics.     
 
The overall objective of this study is to determine if asthmatics overall have an impaired 
influenza vaccine response and if obesity furthers reduces the response.  Results from this study 
can lend insight into an asthmatic’s immune response and we can attempt to identify mechanisms 
that affect their immune response to ultimately develop specific asthmatic preventative and 
treatment measures to the influenza virus.   
 
II.   Introduction  
 
Asthma occurs on average 1 in 12 adults.  In the last decade, the proportion of people in the 
United States with asthma grew by 15%1.  Asthma is characterized as a chronic disease that 
involves inflammation of the pulmonary airways and bronchial hyper-responsiveness that results 
in lower airway obstruction.  Inflammation occurs due to bronchial hyper-responsiveness to 
certain triggers including methacholine and histamine or environmental factors such as cold air, 
exercise, viral upper respiratory infection, cigarette smoke, and respiratory allergens.  Asthmatics 
generally have different levels of immune cells: increased numbers of eosinophils, neutrophils, 
lymphocytes and plasma cells in bronchial tissues, bronchial secretions and mucus.  The Th2 
subset of activated T-lymphocytes produce interleukins (IL-4, IL-5, and IL-13) that signal the 
switch from IgM to IgE antibodies.  IgE antibodies release histamine and other mediators that 
stimulate airway inflammation.  The repeated cycles of inflammation in the lungs with injury to 
pulmonary tissues followed by repair leads to long-term structural changes of the airway3.  
When asthmatics contract the influenza virus, the swelling and sensitivity in the airways 
worsen and the flu infection in the lungs triggers or worsens asthmatic symptoms.  Furuya et. al 
used a mouse-model to determine that there was an increased susceptibility of mice with induced 
asthma to secondary flu virus.  They suggested an impaired humoral immune function as the 
cause.  Papadapoulous and colleagues isolated PBMCs from asthmatics and stimulated them with 
rhinovirus, the most common viral infectious agents in humans and the predominant cause of the 
common cold4.  They found significantly lower levels of gamma interferon and IL-12.  IL-12, 
produced by dendritic cells, macrophages, and neutrophils, is involved in differentiation of naïve 
T cells to Th1 cells which are involved in stimulating phagocyte-dependent protective responses, 
macrophage activation and cell-mediated immunity.  They also found higher levels of IL-4 and 
IL-10; IL-10 suppresses macrophage and dendritic cell function, IL-4 differentiates naive cells 
into Th2 cells.  Th2 promotes class switching of antibodies, one of the functions is switching to 
produce more allergen response antibodies (IgE)4.  The balance between Th1 and Th2 is 
necessary for optimal immune function, but in asthmatics Th2 appears to dominate, suggesting 
that when asthmatics are infected with virus, their Th1 immune response is suboptimal.  Since 
the immune function of asthmatics has been shown to be imbalanced, not only in bronchial 
tissues, but also systematically, it can be predicted that asthmatics will have a lesser immune 
response upon vaccination than their matched controls.  
The 2014-2015 vaccine was made to protect against an A/California/7/2009 (H1N1)-like 
virus, an A/Texas/50/2012 (H3N2)-like virus and a B/Massachusetts/2/2012-like virus.  In the 
2014-2015 flu season, influenza A (H3N2) predominated while influenza A (H1N1) was 
identified less frequently.  For this study, H3N2 and H1N1 virus strains were chosen to best 
mirror the 2014-2015 vaccine strains.  A recent study found that vaccine reduces the risk of flu 
illness approximately 50-60% among the overall population.  The effectiveness of a vaccine 
depends on characteristics of the person being vaccinated and the “match” between flu virus’s 
vaccine and circulating virus.  The Centers for Disease Control and Prevention (CDC) found the 
effectiveness of the 2014-2015 flu vaccine was 23% for all ages, but for influenza A H3N2 
viruses for all ages was 13%.  The CDC concluded that more than 80% of H3N2 viruses had 
“drifted” from the original predicted A/Texas/50/2010 H3N25.            
 
III.   Methods  
 
Choosing Subjects: Asthmatics and Matched Controls from 2014-2015 Beck Lab Flu Study  
Influenza study participants for 2014-2015 were assessed through REDcap database.  Asthmatic 
subjects were determined based on self-reported medical history; demographic information was 
then reviewed to determine matched control subjects.  Asthmatic and control subjects were 
matched based on sex, age, race and smoking status.  A total of 35 subjects were selected—17 
asthmatic and 17 controls.  Table 1 shows a demographic summary of the subjects. 
 





 Asthmatic  Control  
Variable  Value Value 
Sex-no. %   
      Male 3 (17.65%) 3 (17.65%) 
      Female 14(82.35%) 14(82.35%) 
Age-yr.   
      Mean  46.19 44.42 
      Standard Deviation ±11.84 ±12.37 
Race   
      Caucasian/White 9 (52.94%) 10 (58.82%) 
      Black/African America 6(35.29%) 7 (41.18%) 
      Asian 1 (5.88%)  
      Other/mixed 1(5.88%)   
BMI   
     underweight  0 (0%) 0 (0%) 
     normal 4 (23.53%) 5 (29.41%) 
Overweight   2 (11.76%) 1 (5.88) 
Obese I 6 (35.29%) 9 (52.94%) 
Obese II  5 (29.41%) 2 (11.76%) 
Smoker    
      Yes  10 (58.82%) 11 (64.71%) 
      No  4 (23.53%) 6 (35.29%) 
Previous 3 (17.65%) 0 ()%) 
Serum Isolation: 
A tube of blood was drawn and allowed to clot at room temperature. After an overnight 
incubation at 4o C, the serum was removed and stored frozen until utilized.   
 
Influenza HAU Titer 
 
Turkey red blood cells (TRBCs) were washed and suspended of 0.05% was prepared by adding 
2-4 mL of RBCs to a 15-mL conical tube, 10 mL of sterile PBS was added and the tube was 
centrifuged for 10 minutes at 4°C, 270g, 5 deceleration.  This was repeated two times and the 
size of the RBC pellet was estimated after the third centrifuge spin.  Judging by the packed 
TRBC pellet, DPBS was added to yield a 0.5% packed RBC suspension. Two-fold virus 
dilutions were prepared to reach a dilution of 80 HAU/50 microliters and the diluted virus was 
tested using the HAU procedure.  Both H2N3 and H1N1 viruses were prepared in this manner 
and diluted to 80 HAU/50 microliters.  Both viral strains were grown in embyonated chicken 
eggs.   
 
 
Influenza HAI Titer 
 
Receptor Destroying Enzyme, RDE, was prepared and serum samples were treated and incubated 
at 37°C overnight.  The RDE-treated serum was then heated at 56°C for 1 hour to inactivate the 
RDE.  Samples were allowed to cool to room temperature and 6 parts of physiological saline was 
added.  The samples were frozen for at least 4 hours before use (final dilution of serum is 1:10).   
TRBCs at 0.5%, were prepared as described above for HAU. Serum was serially diluted in    
v-bottom culture plates.  
The plate was set as wells 1-8 with duplicates of pre and post vaccination serum samples 
for asthmatic and matched control subjects.  Wells 9 and 10 labeled as negative control (TRBCs, 
4 HAU virus, PBS), 11 as HAU control (virus only) and 12 as TRBC control (TRBCs, PBS).  
PBS ( 25 µL) was added to all wells except for the first row (A).  50 microliters of serum sample 
(diluted 1:10 from RDE treatment) was added to row A, columns 1-8, done in duplicate.  PBS 
(50 µL) was added to Row A, Column 9 and 10.  Appropriate influenza virus (8 HAU/50 µL) 
was added to Row A column 11.  For column 12, 50 µL of PBS was added. Two-fold serial 
dilutions were performed for the entire plate by transferring 25 µL from one row to the next; the 
final 25 µL from Row H was discarded.  
Influenza virus (H2N2 or H1N1;8 HAU/50 µL) was added to all well columns 1-10, 25 
µL of PBS were added to wells of column 11 and 12.  The plate was then covered and incubated 
at room temperature for 15 minutes.  TRBC (0.05% TRBC, 50 µL)  was added to each well 
following incubation. The plate was then covered and incubated at room temperature for 20 
minutes, and checked every 5 minutes to maintain optimal reading until the plate was read.  This 
was done for each asthmatic subject and matched control.       
 
    
Antibody Quantification 
 
HAI titer for subjects was determined by the serum dilution at which there was no longer a pellet 
in the well and hemaglutination began to occur.  Hemaglutination is the lattice formation caused 
by the virus binding to the turkey red blood cells (TRBC).  If there is not a high enough antibody 
: virus ratio; instead of binding to the subject’s antibody, the virus binds to the TRBC, causing 





Measures of significance were analyzed via two-way ANOVA; p-value of less than 0.05 was 
considered statistically significant.     
BMI was assessed as a potential confounder using XY correlation Spearman test; p-value of less 
than 0.05 was considered statistically significant.   
 
 
IV.   Results 
 
Vaccination results in an increase humoral immune response 
 
Following vaccination, both asthmatic and control groups had a significant increase in antibody 
titer, showing that vaccination did improve the humoral immune response in the study population 
(H3N2 p-value 0.0044, H1N1 p-value 0.0030).  Individuals are considered “protected,” meaning 
the influenza virus will have little to no effect on them, if they posses an HAI titer of 40 or 
above6, although not everyone who reaches this titer are indeed protected. Using the cut-off of 
40, the H3N2 pre-vaccination antibody titer, 14 individuals in the control group were protected, 
possessing an HAI titer of 40 or greater while 3 individuals were unprotected.  Post-vaccination, 
all 17 individuals were protected.  In individuals with asthma, pre-vaccination, 5 were protected 
while 12 were unprotected.  Following vaccination, all 17 were protected.  Seroconversion, 
which is converting from an antibody titer lower than 40 pre-vaccination to an antibody titer 
higher than 40 post-vaccination occurred in 6 control individuals and 13 asthmatic individuals 
(figure 1).  
For the H1N1 HAI titer pre-vaccination of 40 or more, 14 individuals in the control group 
were protected while 3 individuals were unprotected.  Post-vaccination, again, all 17 were 
protected.  In asthmatic individuals,  8 were protected pre-vaccine and 16 were protected post 
vaccine.  Seroconversion occurred in 9 asthmatic individuals and 3 control individuals (figure 2).    
 
Figure 1. HAI Results for Asthmatic and Non-Asthmatic pre and post-Vaccination using H3N2 

















































































































Individuals with Asthma have a lower initial immune response than Controls   
 
The antibody titer for H3N2 was significantly lower in asthmatic individuals compared with the 
non-asthmatic controls (Figure 1).  This finding implies that asthmatics, compared with non-
asthmatics, have less ability to maintain their antibody titer over time.  However, post-
vaccination, asthmatic antibody titers appeared to increase to reach at or above the antibody titer 
of their matched controls.  Interaction was significant (p-value 0.0056) meaning there is a 
significant difference between asthmatic and non-asthmatic immune response pre to post 
vaccination.  Differences between asthmatic and control means was insignificant (p-value 0.82), 
while variation in subjects when matched was significant (p-value 0.029). 
For H1N1, a similar trend can be observed with asthmatic individuals having a lower pre-
vaccine HAI titer than their controls (figure 2).  However, the interaction was not significant in 
this case (p-value 0.87) but differences between asthmatic and control means were marginally 
insignificant (p-value 0.06).          
 
Table 2. P-values for sources of Variation in H3N2 and H1N1 data sets 
 
 
Asthmatic individuals had a higher fold increase in HAI Titer    
 
Pre to post vaccine, asthmatic individuals had a general trend of a greater fold increase for both 
virus strains (Figure 3 and 4).  For the H3N2 virus strain, 75% of the asthmatic fold increase 
values were higher than 8.0 while control 75th percentile fold increase was 4.0.  The mean for 
asthmatic fold increase was 8.59 with standard deviation 14.74 and standard error 3.575.  The 
control mean fold increase was 4.18 with standard deviation 4.76 and standard error 1.15.  For 
the H1N1 virus strain the 75th percentile for titer fold increase was the same as the H3N2 fold 
increase for both asthmatics (8.0) and controls (4.0).  The mean for asthmatic fold increase was 
4.82 with a standard deviation of 3.80 and standard error of 0.9205.  Control fold increase mean 





Interaction Vaccination Asthma Subjects 
Matching
  
H3N2 0.0056* 0.0044* 0.8242 0.0291* 
H1N1 0.8720 0.0014* 0.0626 <0.0001* 
  
Figure 3. Fold increase in HAI titer pre to post        Figure 4. Fold increase in HAI Titer pre to 
post vaccination in control and asthmatic subjects   Vaccination in control and asthmatic subjects  




BMI Confounder Assessment  
 
With the H3N2 virus, there was no significant correlation between BMI and HAI titer for 
asthmatic and control groups both pre and post vaccination (Table 3).   
With the H1N1 virus, again, there was no significant correlation between BMI and HAI titer for 
asthmatic and control groups both pre and post vaccination (Table 3).   
 









H3N2 0.5277 0.4068 0.9794 0.5996 
H1N1 0.4303 0.6501 0.6713 0.7337 
 
 
V.   Discussion  
 
Different factors influence an individual’s susceptibility to influenza including 
chronic illnesses, pregnancy, obesity, and age (children and older adults are more at risk 
groups).  Those over the age of 65 are considered at higher risk to influenza because of a 
weakened immune system, but age was not considered a confounder in this study because 
only subjects under 65 were selected; the mean age of subjects was 45.3 with standard 
deviation 12.0.	   Using a mouse-model study, the Beck lab has studied the effects of 
obesity on the response to influenza virus infection and found that obese mice have a 
60% mortality rate from influenza infection while lean mice have a 10% mortality rate.  
Obesity is therefore associated with a weaker immune response to influenza infection6.    




























































and control groups since 15 (44.12%) sample subjects had a BMI of 3 and 7 (20.59%) 
had a BMI of 4.  However, obesity was determined not to influence the outcome, as there 
was no significance in correlation between BMI and HAI titer for either H3N2 or H1N1 
virus strains.   
The effectiveness of influenza vaccination in people with asthma against influenza 
and related complications is not well established.  Previous studies have found asthmatics 
have different concentrations of immune cells and essentially a different immune system 
make-up than those without asthma.  The influenza virus is a trigger that causes 
inflammation in the airways of people with asthma, resulting in severe complications, 
hospitalization, or even death.  Because the asthmatic response to influenza infection is 
severe, protection against infection should be a top priority. Asthmatic immune response 
to influenza needs to be better understood.    
From the results of this study, there is a clear trend of asthmatics having a lower 
antibody titer upon vaccination with both H3N2 and H1N1 virus strains than their 
matched controls pre-vaccination.  Using the H3N2 virus strain, 70.59% of the asthmatic 
subjects were unprotected pre-vaccine, having an HAI titer of less than 40, while only 
17.65% of control subjects were unprotected pre-vaccine.  Post-vaccination, in both 
groups, all subjects were protected indicating a general increase in antibody 
concentration.  The H1N1 virus strain pre-vaccination antibody titer was higher for 
asthmatics with 52.9% unprotected, but still much higher percentage than the control 
group in which 82.4% of the group was protected pre-vaccination.  Post-vaccination, 
100% of the control group reached protection while 94.1% of the asthmatic group 
reached protection (only 1 out of 17 remained unprotected).  The effectiveness of the 
vaccine was significant in both groups, indicating that vaccination is associated with 
antibody increase and therefore a greater immune response upon influenza vaccination. 
 Since many asthmatics began unprotected and then seroconverted, their fold 
increase in antibody concentration pre to post vaccination in general was greater than the 
control group.  This indicates that while individuals with asthma have an initial antibody 
titer less than that of non-asthmatics, their secondary response is comparable, suggesting 
vaccination is effective for both asthmatic and non-asthmatic individuals.  Vaccination is 
believed to induce a variable degree of protection (0-80%) against influenza and its 
complications7.  A good antigenic match between circulating influenza virus and the 
strains included in the vaccine is required for optimal protection.  Future studies should 
examine the mechanism behind asthmatic immune response upon primary and secondary 
influenza infection as well as specific immune cell concentrations pre to post influenza 
vaccination.        
This study was limited in that specific antibody concentrations such as interleukin 
levels and other cytokine classes associated with either Th1 or Th2 immunity could not 
be examined through the HAI procedure.  Influenza viruses infect human cells through 
binding of the viral surface hemagglutinin protein to the terminal sialic acid molecules of 
glycoproteins and glycolipids expressed on host cell membranes, which instigates fusion 
of viral and cell membranes8.  Antibodies directed at HA targets on the virus can block 
the virus from binding to host cell membranes. Although this is the best-defined correlate 
of influenza immunity, determinants of influenza immunity in humans are not completely 
understood, and HI antibodies provide only a partial explanation.  Therefore, HAI titer is 
not a direct correlate to influenza immunity.   
Possible sources of heterogeneity among participants could be a cause of variation 
among subjects’ immune response within the asthmatic group.  These include the severity 
of asthma: people with mild to moderate asthma compared with those with severe asthma 
and external factors such as medications used by asthmatic individuals that would effect 
immunity.  Corticosteroid therapy is a treatment for individuals with asthma which is 
known to alter lymphocyte recirculation, inducing lymphocyte death.  An important 
immunosuppressive effect is inhibition of cytokine production.  Individuals on such 
treatment are at increased risk of infection and protective effect of vaccines may be 
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